Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07399678 · ClinicalTrials.gov registry record · Phase 1
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes, sponsored by Alveus Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT07399678 is a Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes that is actively recruiting participants, run by Alveus Therapeutics. The registered enrollment target is 180 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07399678, a Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes, is actively recruiting participants, sponsored by Alveus Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALV-100
Study Locations (1)
Florida
- Clinical Pharmacology of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07399678
The ClinicalTrials.gov registry entry for NCT07399678 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alveus Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Overweight or Obese Adults appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07399678 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07399678 about?
NCT07399678 is a clinical study titled "Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D". A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
What is the current status of trial NCT07399678?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2025-12-29. Estimated completion is 2027-09.
What conditions does trial NCT07399678 study?
This clinical trial studies the following conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes.
What interventions are being tested in trial NCT07399678?
The interventions under investigation include: Placebo (DRUG), ALV-100 (DRUG).
Who is sponsoring clinical trial NCT07399678?
This trial is sponsored by Alveus Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07399678 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight or Obese Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Overweight or Obese Adults
All registered trials for this condition
Overweight or Obese, Type 2 Diabetes
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.